The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Reduction of Cardiovascular Risk by Regression of Electrocardiographic Markers of Left Ventricular Hypertrophy by the Angiotensin-Converting Enzyme Inhibitor Ramipril
Abstract
Background Electrocardiographic markers of left ventricular hypertrophy (LVH) predict poor prognosis. We determined whether the ACE inhibitor ramipril prevents the development and causes regression of ECG-LVH and whether these changes are associated with improved prognosis independent of blood pressure reduction. Methods and Results In the Heart Outcomes Prevention Evaluation (HOPE) study, patients at high risk were randomly assigned to ramipril or placebo and followed for 4.5years. ECGs were recorded at baseline and at study end. We compared prevention/regression and development/persistence of ECG-LVH in the two groups and related these changes to outcomes. At baseline, 676 patients had LVH (321 in the ramipril group and 355 in the placebo group) and 7605 patients did not have LVH (3814 in the ramipril group and 3791 in the placebo group). By study end, 336 patients in the ramipril group (8.1%) compared with 406 in the placebo group (9.8%) had development/persistence of LVH; in contrast, 3799 patients in the ramipril group (91.9%) compared with 3740 in the placebo group (90.2%) had regression/prevention of LVH ( P =0.007). The effect of ramipril on LVH was independent of blood pressure changes. Patients who had regression/prevention of LVH had a lower risk of the predefined primary outcome (cardiovascular death, myocardial infarction, or stroke) compared with those who had development/persistence of LVH (12.3% versus 15.8%, P =0.006) and of congestive heart failure (9.3% versus 15.4%, P <0.0001). Conclusions The ACE inhibitor ramipril decreases the development and causes regression of ECG-LVH independent of blood pressure reduction, and these changes are associated with reduced risk of death, myocardial infarction, stroke, and congestive heart failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Levy, D., Garrison, R. J., Savage, D. D., Kannel, W. B., & Castelli, W. P. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005313222203 · Cited by 5,699
(1999) · Journal of Hypertension · doi:10.1097/00004872-199917020-00001 · Cited by 3,695
Sokolow, M., & Lyon, T. P. (1949) · American Heart Journal · doi:10.1016/0002-8703(49)90562-1 · Cited by 1,980
Yusuf, S., & Jha, P. (2000) · Cited by 895
Self-citationKANNEL, W. B., GORDON, T., & OFFUTT, D. (1969) · Annals of Internal Medicine · doi:10.7326/0003-4819-71-1-89 · Cited by 753
Levy, D., Salomon, M., D'Agostino, R. B., Belanger, A. J., & Kannel, W. B. (1994) · Circulation · doi:10.1161/01.cir.90.4.1786 · Cited by 619
Schmieder, R. E. (1996) · JAMA · doi:10.1001/jama.1996.03530430051039 · Cited by 604
Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection.
Lonn, E. M., Yusuf, S., Jha, P., Montague, T. J., Teo, K. K., Benedict, C. R., & Pitt, B. (1994) · Circulation · doi:10.1161/01.cir.90.4.2056 · Cited by 503
Self-citation
Cited by
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
Writing Committee Members, Greenland, P., Alpert, J. S., Beller, G. A., Benjamin, E. J., Budoff, M. J., Fayad, Z. A., Foster, E., Hlatky, M. A., Hodgson, J. M., et al. (2010) · Circulation · doi:10.1161/cir.0b013e3182051b4c · Cited by 1,873
Cardiac Hypertrophy: The Good, the Bad, and the Ugly
Frey, N., & Olson, E. N. (2003) · Annual Review of Physiology · doi:10.1146/annurev.physiol.65.092101.142243 · Cited by 1,449
2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults
Greenland, P., Alpert, J. S., Beller, G. A., Benjamin, E. J., Budoff, M. J., Fayad, Z. A., Foster, E., Hlatky, M. A., Hodgson, J. M., Kushner, F. G., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.09.001 · Cited by 1,324
Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations
Vasan, R. S. (2006) · Circulation · doi:10.1161/circulationaha.104.482570 · Cited by 1,212
AHA/ACCF/HRS Recommendations for the Standardization and Interpretation of the Electrocardiogram
Rautaharju, P. M., Surawicz, B., & Gettes, L. S. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.12.014 · Cited by 1,016
Prognostic Significance of Left Ventricular Mass Change During Treatment of Hypertension
Devereux, R. B. (2004) · JAMA · doi:10.1001/jama.292.19.2350 · Cited by 881
Hypertrophy of the Heart: A New Therapeutic Target?
Frey, N., Katus, H. A., Olson, E. N., & Hill, J. A. (2004) · Circulation · doi:10.1161/01.cir.0000120390.68287.bb · Cited by 851
Aurigemma, G. P., & Gaasch, W. H. (2004) · New England Journal of Medicine · doi:10.1056/nejmcp022709 · Cited by 764
Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney
Crowley, S. D., Gurley, S. B., Herrera, M. J., Ruiz, P., Griffiths, R., Kumar, A. P., Kim, H.-S., Smithies, O., Le, T. H., & Coffman, T. M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605545103 · Cited by 714
Aronow, W. S., Fleg, J. L., Pepine, C. J., Artinian, N. T., Bakris, G., Brown, A. S., Ferdinand, K. C., Forciea, M. A., Frishman, W. H., Jaigobin, C., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31821daaf6 · Cited by 614
Chang, S., McKinsey, T. A., Zhang, C. L., Richardson, J. A., Hill, J. A., & Olson, E. N. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.19.8467-8476.2004 · Cited by 613
Verma, S., Mazer, C. D., Yan, A. T., Mason, T., Garg, V., Teoh, H., Zuo, F., Quan, A., Farkouh, M. E., Fitchett, D. H., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.042375 · Cited by 572
ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly
Aronow, W. S., Fleg, J. L., Pepine, C. J., Artinian, N. T., Bakris, G., Brown, A. S., Ferdinand, K. C., Ann Forciea, M., Frishman, W. H., Jaigobin, C., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.01.008 · Cited by 514
Devereux, R. B., Dahlöf, B., Gerdts, E., Boman, K., Nieminen, M. S., Papademetriou, V., Rokkedal, J., Harris, K. E., Edelman, J. M., & Wachtell, K. (2004) · Circulation · doi:10.1161/01.cir.0000141573.44737.5a · Cited by 470
Hancock, E. W., Deal, B. J., Mirvis, D. M., Okin, P., Kligfield, P., & Gettes, L. S. (2009) · Circulation · doi:10.1161/circulationaha.108.191097 · Cited by 441
AHA/ACCF/HRS Recommendations for the Standardization and Interpretation of the Electrocardiogram
Hancock, E. W., Deal, B. J., Mirvis, D. M., Okin, P., Kligfield, P., & Gettes, L. S. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.12.015 · Cited by 435
Verdecchia, P., Staessen, J. A., Angeli, F., de Simone, G., Achilli, A., Ganau, A., Mureddu, G., Pede, S., Maggioni, A. P., Lucci, D., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61340-4 · Cited by 434
Guidelines for the management of arterial hypertension
van de Borne, P. (2014) · Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) · doi:10.2143/ac.69.1.3011345 · Cited by 350
Left ventricular hypertrophy and hypertension
Yildiz, M., Oktay, A. A., Stewart, M. H., Milani, R. V., Ventura, H. O., & Lavie, C. J. (2020) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.11.009 · Cited by 333
Verdecchia, P. (2003) · American Journal of Hypertension · doi:10.1016/s0895-7061(03)01018-5 · Cited by 310
Augmentation index as a measure of peripheral vascular disease state
Nichols, W. W., & Singh, B. M. (2002) · Current Opinion in Cardiology · doi:10.1097/00001573-200209000-00016 · Cited by 304
Assessment of Left Ventricular Mass by Cardiovascular Magnetic Resonance
Myerson, S. G., Bellenger, N. G., & Pennell, D. J. (2002) · Hypertension · doi:10.1161/hy0302.104674 · Cited by 298
Sriramula, S., Haque, M., Majid, D. S. A., & Francis, J. (2008) · Hypertension · doi:10.1161/hypertensionaha.107.102152 · Cited by 278
Okin, P. M., Devereux, R. B., Jern, S., Kjeldsen, S. E., Julius, S., Nieminen, M. S., Snapinn, S., Harris, K. E., Aurup, P., Edelman, J. M., et al. (2003) · Circulation · doi:10.1161/01.cir.0000083724.28630.c3 · Cited by 257
Kamat, A. M., Flaig, T. W., Grossman, H. B., Konety, B., Lamm, D., O'Donnell, M. A., Uchio, E., Efstathiou, J. A., & Taylor, J. A. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2015.58 · Cited by 252
Bönner, G., Bakris, G. L., Sica, D., Weber, M. A., White, W. B., Perez, A., Cao, C., Handley, A., & Kupfer, S. (2013) · Journal of Human Hypertension · doi:10.1038/jhh.2013.6 · Cited by 61
Best Strategies for Hypertension Management in Type 2 Diabetes and Obesity
Allcock, D. M., & Sowers, J. R. (2010) · Current Diabetes Reports · doi:10.1007/s11892-010-0100-z · Cited by 35
Metadata
- Authors
- Mathew, J., Sleight, P., Lonn, E., Johnstone, D., Pogue, J., Yi, Q., Bosch, J., Sussex, B., Probstfield, J., & Yusuf, S.
- Venue
- Circulation
- Published
- 2001-10-02
- Volume
- 104
- Issue
- 14
- Pages
- 1615-1621
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2109041435
- Cited by
- 557
- References
- 19
- FWCI
- 21.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.